Big Money Sentiment decreased to 1.14 in 2018 Q4. It has change of 0.08, from 2018Q3’s 1.22. The ratio dropped due to Boston Scientific Corporation positioning: 46 sold and 195 reduced. 78 funds took stakes and 197 increased stakes. Investors holded 1.20 billion in 2018Q3 but now own 1.23 billion shares or 2.00% more.
Moreover, Argent Capital Limited Liability Corporation has 2.3% invested in Boston Scientific Corporation (NYSE:BSX) for 1.29M shs. Thrivent For Lutherans, Minnesota-based fund reported 86,881 shs. Redwood Invests Limited Liability Corp, a Massachusetts-based fund reported 234,963 shs. Meyer Handelman Company has 0.05% invested in Boston Scientific Corporation (NYSE:BSX) for 26,400 shs. Benjamin F Edwards And holds 6,616 shs. Prudential Public Limited Company has invested 0% in Boston Scientific Corporation (NYSE:BSX). Moreover, Bluemountain Cap Mgmt Ltd has 0.06% invested in Boston Scientific Corporation (NYSE:BSX) for 62,198 shs. Moreover, Arizona State Retirement has 0.18% invested in Boston Scientific Corporation (NYSE:BSX). Millennium Management Limited Liability invested in 0.26% or 4.69M shs. Proshare Ltd invested in 0.06% or 242,166 shs. Sumitomo Mitsui Asset Mngmt Communication Ltd reported 131,716 shs. Boston Ptnrs holds 2.13M shs. Moreover, Hodges Mngmt has 1.17% invested in Boston Scientific Corporation (NYSE:BSX) for 294,899 shs. Braun Stacey Inc holds 344,375 shs or 0.96% of its capital. South Street Advsrs Ltd Liability Corporation has invested 4.1% of its capital in Boston Scientific Corporation (NYSE:BSX).

Boston Scientific Corporation registered $11.00 million net activity with 0 insider purchases and 17 sales since November 1, 2018. On Friday, November 9 $879,886 worth of stock was sold by Thepaut Eric Francis Yves. Shares for $154,000 were sold by Butcher Arthur C. On Friday, February 1 Pierce David A sold $190,750 worth of Boston Scientific Corporation (NYSE:BSX) or 5,000 shs. Nanavaty Maulik sold $107,727 worth of Boston Scientific Corporation (NYSE:BSX) on Tuesday, January 15. On Thursday, November 1 116,666 shs were sold by Mahoney Michael F, worth $4.24M. On Friday, November 30 a trade for 6,143 shs valued at $228,090 was made by FUJIMORI YOSHIAKI.

On April, 24 Boston Scientific Corporation (NYSE:BSX)’s earnings release is anticipated by WallStreet, Zacks reports. earnings per share of $0.36 is 9.09 % up from 2018’s $0.33 EPS. If the current earnings per share of $0.36 is accurate, BSX’s profit could hit $500.58 million. After $0.39 EPS report last quarter, Wall Street now sees -7.69 % negative EPS growth of Boston Scientific Corporation. The stock decreased 0.50% or $0.19 during the last trading session, hitting $37.73.Boston Scientific Corporation has volume of 4.12 million shares. Since April 13, 2018 BSX has risen 52.08% and is uptrending. The stock outperformed the S&P500 by 47.71%.

Boston Scientific Corporation (NYSE:BSX) Ratings Coverage

In total 6 analysts cover Boston Scientific (NYSE:BSX). “Buy” rating has 6, “Sell” are 0, while 0 are “Hold”. (NYSE:BSX) has 100% bullish analysts. 7 are the (NYSE:BSX)’s ratings reports on Apr 13, 2019 according to StockzIntelligence Inc. On Thursday, October 25 the stock of Boston Scientific Corporation (NYSE:BSX) earned “Buy” rating by Canaccord Genuity. On Friday, October 26 the firm earned “Buy” rating by Argus Research. On Monday, March 18 the stock of Boston Scientific Corporation (NYSE:BSX) has “Buy” rating given by Bank of America.

Boston Scientific Corporation develops, makes, and markets medical devices for use in various interventional medical specialties worldwide.The firm is valued at $52.46 billion. It operates through three divisions: Cardiovascular, Rhythm Management, and MedSurg.The P/E ratio is 31.71. The firm offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; other coronary therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

For more Boston Scientific Corporation (NYSE:BSX) news posted recently go to: Benzinga.com, Streetinsider.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “(BJ), Boston Scientific Corporation (NYSE:BSX) – Port Report: Year After First Salvo, U.S.-China Trade War In Ceasefire, But New Ones Are Starting – Benzinga” posted on April 09, 2019, “Boston Scientific (BSX) Highlights Positive Safety & Efficacy Data for LUMINIZE RF Balloon Catheter During Late-Breaking Clinical Trial – StreetInsider.com” on March 18, 2019, “Boston Scientific buys remaining Millipede shares – Seeking Alpha” with a publish date: December 27, 2018, “Boston Sci’s next gen Watchman device CE Mark’d – Seeking Alpha” and the last “Boston Scientific Q4 2018 Earnings Preview – Seeking Alpha” with publication date: February 05, 2019.